Holen Sie sich die Stockscreener-App
25.10
3.13%
-0.81
Schlusskurs vom Vortag:
$25.91
Offen:
$26.22
24-Stunden-Volumen:
1.81M
Relative Volume:
0.78
Marktkapitalisierung:
$2.58B
Einnahmen:
$164.01M
Nettoeinkommen (Verlust:
$-65.04M
KGV:
-36.54
EPS:
-0.687
Netto-Cashflow:
$-383.84M
1W Leistung:
-8.83%
1M Leistung:
-25.96%
6M Leistung:
-20.47%
1J Leistung:
+19.81%
1-Tages-Spanne:
$24.85
$26.41
1-Wochen-Bereich:
$24.85
$28.13
52-Wochen-Spanne:
$15.60
$38.26
Beam Therapeutics Inc Stock (BEAM) Company Profile
Firmenname
Beam Therapeutics Inc
Sektor
Branche
Telefon
857-327-8775
Adresse
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Compare BEAM vs VRTX, REGN, ARGX, RVMD, ALNY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BEAM
Beam Therapeutics Inc
|
25.10 | 2.58B | 164.01M | -65.04M | -383.84M | -0.687 |
VRTX
Vertex Pharmaceuticals Inc
|
477.36 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.01 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
918.22 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.23 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.77 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-20 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-10-09 | Eingeleitet | Jefferies | Buy |
| 2025-03-28 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-03-10 | Hochstufung | Scotiabank | Sector Perform → Sector Outperform |
| 2025-01-29 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-06 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-07-23 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-01-29 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-12-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-12-08 | Herabstufung | Jefferies | Buy → Hold |
| 2023-10-20 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-20 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2023-03-21 | Eingeleitet | Bernstein | Mkt Perform |
| 2023-02-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-12-20 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2022-12-13 | Eingeleitet | Citigroup | Buy |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2022-04-28 | Eingeleitet | Credit Suisse | Neutral |
| 2022-01-05 | Eingeleitet | Guggenheim | Buy |
| 2021-10-19 | Eingeleitet | SVB Leerink | Outperform |
| 2021-09-24 | Fortgesetzt | Stifel | Buy |
| 2021-09-10 | Eingeleitet | BofA Securities | Buy |
| 2021-05-11 | Eingeleitet | Redburn | Buy |
| 2021-05-04 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2021-03-01 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2021-02-16 | Eingeleitet | Wells Fargo | Overweight |
| 2021-01-29 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-01-06 | Eingeleitet | Stifel | Hold |
| 2020-08-05 | Eingeleitet | William Blair | Outperform |
| 2020-03-02 | Eingeleitet | Barclays | Overweight |
| 2020-03-02 | Eingeleitet | JP Morgan | Overweight |
| 2020-03-02 | Eingeleitet | Jefferies | Buy |
| 2020-03-02 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Beam Therapeutics Inc Aktie (BEAM) Neueste Nachrichten
First Trust Heitman Glbl Prm Rl Estt ETF (PRME) stock price, news, quote and history - Yahoo Finance UK
Beam Therapeutics Inc. (BEAM) Stock Price, News, Quote & History - Yahoo! Finance Canada
Beam Therapeutics Inc. (BEAM) stock price, news, quote and history - Yahoo Finance Australia
Beam Therapeutics to present BEAM-302 data at September conference By Investing.com - Investing.com Nigeria
Beam Therapeutics to present BEAM-302 data at September conference - Investing.com
Beam's One-Time Alpha-1 Treatment Data Update Set for Sept. 8 - Stock Titan
Beam Therapeutics Stock 9-Day Losing Spree: Stock Falls 31% - Trefis
9 Red Days In A Row: Beam Therapeutics Stock Is Down 31% - Trefis
8 Red Days In A Row: Beam Therapeutics Stock Is Down 27% - Trefis
Cathie Wood Is Buying This Up-and-Coming Biotech Stock. Should You Follow Her Lead? - The Motley Fool
ETFs Investing in Beam Therapeutics, Inc. Stocks - TradingView
8-Day Sell-Off Sends Beam Therapeutics Stock Down 27% - Trefis
Understanding the Setup: (BEAM) and Scalable Risk - Stock Traders Daily
BEAM Stock's Gains Fade Despite Promising Data Rare Liver Disease Treatment Data - Stocktwits
Beam Therapeutics Stock 6-Day Losing Spree: Stock Falls 19% - Trefis
6 Red Days In A Row: Beam Therapeutics Stock Is Down 19% - Trefis
Bank of America Securities Maintains Buy Rating for Beam Therapeutics (BEAM) - Yahoo Finance
Prime Medicine (PRME) Reaches Positive Resolution to Arbitration with Beam Therapeutics - Yahoo Finance
4 Best CRISPR Companies to Buy in 2026 and How to Invest - The Motley Fool
BEAM News | BEAM THERAPEUTICS INC (NASDAQ:BEAM) - ChartMill
What Were the Key Highlights from Beam's RBC Conference Presentation - Kavout | AI
Prime Medicine gains after winning arbitration with Beam Therapeutics - MSN
Beam Therapeutics Inc. (BEAM) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Beam Therapeutics (BEAM) Short Interest & Short Float | Updated Jul 2026 - MarketBeat
Beam Therapeutics (BEAM) Faces New AATD Rival PM647 Ruling What Does It Signal Strategically? - Yahoo Finance
Prime Editing Clears IP Fight, Sets Q3 Filing for First Liver-Targeted AATD Drug - Tech Times
Prime Medicine Beats Beam Therapeutics In Patent DisputeBut Both Are Investable (PRME) - Seeking Alpha
BofA Securities Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $47 - Moomoo
BEAM Reiterated by B of A Securities -- Price Target Maintained at $47 - GuruFocus
Prime Medicine Jumps 15% as Arbitration Win Clears Path for AATD Gene-Editing Human Trials - finance.biggo.com
TD Cowen reiterates Buy on Prime Medicine stock after arbitration win By Investing.com - Investing.com South Africa
Prime Medicine Receives Favorable Ruling in Beam Therapeutics License Arbitration; Shares Rise - marketscreener.com
Prime Medicine Secures Favorable Arbitration Ruling in Beam Therapeutics Case - Benzinga
PRME Surges 15% After Winning Arbitration Against Beam — Clears Path To Human Trials For Its Gene-Editing Drug - Stocktwits
BofA reiterates Beam Therapeutics stock rating after arbitration ruling By Investing.com - Investing.com Nigeria
BofA reiterates Beam Therapeutics stock rating after arbitration ruling - Investing.com
Prime Medicine wins binding arbitration against Beam Therapeutics - grafa.com
Prime Medicine stock surges after winning arbitration with Beam By Investing.com - Investing.com South Africa
Why is Beam Therapeutics stock sliding today? By Investing.com - Investing.com Canada
Prime Medicine Announces Positive Resolution to Arbitration with Beam Therapeutics - The Manila Times
Prime Medicine (NASDAQ: PRME) cleared of breach in Beam arbitration ruling - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
A New CRISPR "DNA Shredder" Could Change Gene-Editing -- What It Means for CRISPR Therapeutics - Yahoo Finance
Prime wins gene editing dispute; Saol claims latest post-Makary FDA reversal - Yahoo Finance
H.C. Wainwright reiterates Beam Therapeutics stock rating on BLA progress By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates Beam Therapeutics stock rating on BLA progress - Investing.com
H.C. Wainwright Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $80 - Moomoo
Russell Value Index Additions Could Be A Game Changer For Beam Therapeutics (BEAM) - simplywall.st
Beam Therapeutics stock hits 52-week high at 36.89 USD - Investing.com UK
Beam Therapeutics stock hits 52-week high at 36.89 USD By Investing.com - Investing.com Nigeria
Finanzdaten der Beam Therapeutics Inc-Aktie (BEAM)
Umsatz
Nettogewinn
Free Cashflow
ENV
Beam Therapeutics Inc-Aktie (BEAM) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Evans John M. | CEO |
Jun 30 '26 |
Option Exercise |
1.03 |
25,000 |
25,750 |
1,072,205 |
| Evans John M. | CEO |
Jun 29 '26 |
Option Exercise |
0.76 |
25,000 |
19,031 |
1,072,205 |
| Evans John M. | CEO |
Jun 29 '26 |
Sale |
35.49 |
25,000 |
887,352 |
1,047,205 |
| Evans John M. | CEO |
Jun 30 '26 |
Sale |
34.31 |
25,000 |
857,685 |
1,047,205 |
0.46%
0.84%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):